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A catalog of common, intermediate and well-documented (CIWD) HLA-A, -B,
-C, -DRB1, -DRB3, -DRB4, -DRB5, -DQB1 and -DPB1 alleles has been compiled
from over 8 million individuals using data from 20 unrelated hematopoietic
stem cell volunteer donor registries. Individuals are divided into seven geo-
graphic/ancestral/ethnic groups and data are summarized for each group and
for the total population. P (two-field) and G group assignments are divided into
one of four frequency categories: common (≥1 in 10 000), intermediate (≥1 in
100 000), well-documented (≥5 occurrences) or not-CIWD. Overall 26% of
alleles in IPD-IMGT/HLA version 3.31.0 at P group resolution fall into the three
CIWD categories. The two-field catalog includes 18% (n = 545) common, 17%
(n = 513) intermediate, and 65% (n = 1997) well-documented alleles. Full-field
allele frequency data are provided but are limited in value by the variations in
resolution used by the registries. A recommended CIWD list is based on the
most frequent category in the total or any of the seven geographic/ancestral/eth-
nic groups. Data are also provided so users can compile a catalog specific to the
population groups that they serve. Comparisons are made to three previous
CWD reports representing more limited population groups. This catalog, CIWD
version 3.0.0, is a step closer to the collection of global HLA frequencies and to
a clearer view of HLA diversity in the human population as a whole.
KEYWORD S
alleles, ethnic groups, gene frequency, HLA
1 | INTRODUCTION
Identification of the highly polymorphic HLA genes
(HLA-A, -B, -C, -DR, -DQ, and -DP) in the clinical lab-
oratory (ie, HLA “typing”) ensures that hematopoietic
stem cell donor and recipient are HLA matched at
high-resolution, enabling engraftment of donor cells
and avoiding detrimental immune responses (eg, graft
vs host disease).1,2 In solid organ transplantation, eval-
uation of HLA differences is used to select donors who
will not react with or induce donor-specific antibodies
to avoid graft rejection.3-5 Other uses of HLA typing
are to guide immunotherapies,6 prevent adverse drug
reactions,7 diagnose autoimmune diseases,8 and inform
HLA population genetics.9 The frequency of specific
HLA alleles in human populations varies, influenced
by natural selection.9
The almost exponential increase in the known HLA
alleles over time10,11 has been paralleled by changes in the
methods used to type those alleles. Serologic typing of
HLA proteins was replaced by DNA-based methods that
identified the presence or absence of specific polymor-
phisms through the binding of oligonucleotide probes or
primers. Next, DNA sequencing, first by Sanger-based pro-
tocols and now by next generation sequencing, has
defined the nucleotide sequence of large segments of each
HLA gene. Variation in the ability to assign polymorphic
residues to one haplotype vs the other has also varied with
the reagents and methods used producing, in many cases,
ambiguity in the specific genotype carried by an individ-
ual. The history of all of these changes in the known allele
database and the typing methods is reflected in the wide
variety of HLA assignments found in the millions of indi-
viduals listed in donor registries around the world.12,13
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An added challenge is that the method(s) and reagents
used are not always linked to the HLA assignment gener-
ated, especially within the databases of unrelated hemato-
poietic stem cell donor registries. This makes it difficult to
determine if the assignment truly reflects any unresolved
ambiguity. For example, B*51:01:01:01 might be assigned
by a laboratory based on a sequence that includes all
exons and introns but not the 30 untranslated region
(UTR). Alleles identified later that differ in this UTR (eg,
B*51:01:01:02) make the assignment ambiguous. Likewise,
it is not clear from the HLA assignment what level of reso-
lution was applied. For example, a two-field assignment,
A*01:01, is not clear as to what alleles are included (eg,
A*01:103 because it is included in the A*01:01:01G group)
or excluded (A*01:87N because it is a nonexpressed allele
and the assignment was provided without the “P” because
of registry specifications). This variation has presented a
major challenge for determining the frequency of individ-
ual alleles.13,14
Prompted by the complexity of HLA typing in the face
of ever-increasing allele numbers, attempts have been
made to classify alleles based on their frequencies. In this
way, if a laboratory resolves an HLA assignment down to
several alternative genotypes (ie, ambiguous result), the
laboratory might consider the allele frequencies associ-
ated with each genotype in making a final assignment
without further testing. Initially, this effort was intended
to provide guidance for external proficiency testing but
rapidly became a reference for clinical decision making.
The first classification system called the common and
well-documented (CWD) allele catalog was compiled by
the American Society for Histocompatibility and Immu-
nogenetics (ASHI) in 200715 and updated in 2012 as ver-
sion 2.0.016 (Supporting Information Table S1). This
effort was replicated by other worldwide groups, notably
the European Federation for Immunogenetics (EFI
CWD)17 and the China Marrow Donor Program (China
CWD).18 A fourth study, with subjects overlapping the
EFI study, used imputation to predict alleles at two-field
resolution.19 While the precise definitions of common
and well-documented differed somewhat among the
studies, in general, alleles were classified as common if
they were observed in multiple population groups with
frequencies greater than 1 in 1000 in groups of at least
1500 individuals. Well-documented alleles were more
restricted in their distribution with unclear frequencies
but were observed at least five times by DNA sequencing
or three times in a shared haplotype. The remainder of
the alleles were classified as not-CWD.
Solid organ and hematopoietic cell donation and
transplantation programs are found in over 100 countries,
representing nearly 90% of the worldwide population
(https://www.who.int/transplantation/gkt/statistics/en/,
October 2019). Typing of HLA to support this activity is
challenged by the increasing ethnic diversity of the
patient and donor populations including the frequent
international source of unrelated hematopoietic cell trans-
plantation donors.20,21 For these reasons, an investigation
of allele frequencies should take a worldwide focus. The
aim of this study, a component of the 18th International
HLA and Immunogenetics Workshop, was to collate the
most comprehensive and diverse analysis of HLA and
estimate frequencies in different geographic/ancestral/
ethnic population groups.
2 | MATERIALS AND METHODS
World Marrow Donor Association unrelated donor regis-
tries were invited to participate in sharing HLA data for
this study. Donor HLA typing must have met the follow-
ing conditions to be included: New volunteer donor
recruitment testing within the years of 2012-2018 regard-
less of current registry availability status; HLA assign-
ment by sequencing (Sanger or next generation DNA
sequencing) methods with resolution of at least antigen
recognition domain (ARD) exons (ie, Class I exons 2 and
3; Class II exon 2); volunteers included must be consecu-
tive registrants during the period of time of suitable HLA
resolution (not just patient-directed or directed registry
upgrade testing); all HLA types during that time period
must be submitted including those with allelic ambigui-
ties. Supporting Information Table S2 describes the varia-
tions in the HLA nomenclature observed in the dataset.
Twenty registries responded by submitting volunteer
donor data for loci (HLA-A, -B, -C, -DRB1, -DRB3,
-DRB4, -DRB5, -DQB1 and -DPB1) fitting the above con-
ditions (Table 1). Insufficient data were available for
HLA-DQA1 and -DPA1 as these loci are not commonly
typed by registries. Data were provided as a total allele
count assigned to geographic/ancestral/ethnic groups,
hereafter “population groups,” if such data was collected
(Tables 2a and 2b). Ancestry categorization was defined
by each registry and converted into seven population
groups for this study: AFA (African/African American),
API (Asian/Pacific Islands), EURO (European/European
descent), MENA (Middle East/North Coast of Africa),
HIS (South or Central America/Hispanic/Latino), NAM
(Native American) and UNK (unknown/not asked/multi-
ple ancestries/other).
2.1 | Allele designation and resolution
Assignments include only alleles found in IPD-IMGT/
HLA version 3.31.0 from January 2018.11 All assignments
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are evaluated as submitted with the following exceptions
(also described in Supporting Information Table S2):
(a) HLA assignments provided as an NMDP multiple
allele code,22 defined with only alleles in a single G
group,10 are converted to the respective G nomenclature.
(b) Multiple allele-coded assignments that are not the
equivalent of a G assignment (eg, A*01:ANDKJ includes
A*01:01 but also A*01:52 which is not included in
A*01:01:01G) are merged. (c) Assignments reported at
three-field resolution without the addition of the
expected G (eg, A*01:01:01 instead of A*01:01:01G) are
merged into the G group assignment. In these cases, it is
likely that the assignment was made based on the
sequence of the ARD-encoding exons but confirming
information is not available. (d) A summary G value is
based on combining all assignments that would be
included in a G group (eg, A*01:01:01G total includes
assignments of A*01:01:01, A*01:01:01G, A*01:01:01:01,
A*01:04N, etc). (e) Two-field allele summaries are at the
resolution level of P groups; known nonexpressed alleles
(eg, A*01:04N) are listed separately. The P group includes
both G and two-field assignments (eg, B*07:02P total
includes B*07:02, B*07:02P, B*07:02:02, B*07:02:03,
B*07:02:01G, all assignments within the B*07:02:01G
group except nonexpressed alleles, etc). (f) Data submit-
ted with third-field (with or without a G) or fourth-field
nomenclature are used for subset analysis showing allele
occurrence but the main analysis is evaluated based on
the first two fields of the allele name because of inconsis-
tent typing for the third- and fourth-field data across the
cohort. (g) Assignment of novel alleles are assignments
without a nomenclature designation; these assignments
were merged (eg, A*NEW) and included in the analysis.
2.2 | Assignment of allele frequency
categories
The total number of HLA assignments for each locus for
each population group is provided in Table 2b. This








Argentine HSC Donors Registry 129 879 Americas
Bone Marrow Donor Programme Singapore 32 875 Western Pacific
Central Unrelated Potential Bone Marrow Donor
and Cord Blood Registry Poltransplant
6918 European
Czech National Marrow Donors Registry 36 289 European
Danish Stem Cell Donors—West 21 234 European
DKMS (Germany, Polska, UK, India, USA) 5 316 717 Multi-region
Finnish Stem Cell Registry 20 427 European
Gift of Life Marrow Registry 125 489 Americas
Hellenic Transplant Organization (HTO) 121 088 European
India—DATRI Blood Stem Cell Donor Registry 347 989 South East Asia
Israel-Ezer Mizion BMDR 138 175 European
Italian Bone Marrow Donor Registry 30 117 European
Saudi Stem Cell Donor Registry 34 729 Eastern Mediterranean
Kuwait National Stem Cell Registry 673 Eastern Mediterranean
New Zealand Bone Marrow Donor Registry 237 Western Pacific
NMDP/Be The Match-USA and Mexico 1 567 473 Americas
Norwegian Bone Marrow Donor Registry 7202 European
Swiss Blood Stem Cells 84 789 European
Thai National Stem Cell Donor Registry 5000 South East Asia
Tobias Registry of Swedish Bone Marrow Donors 50 502 European
Total 8 077 802
aNumber of donors varied by locus. The largest number is listed.
bRegions and included countries are defined at http://apps.who.int/medicinedocs/en/d/Jwhozip16e/2.html#Jwhozip16e.2
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TABLE 2A Self-reported ancestrya of individuals included in the dataset and the number of P group assignments represented by each
population group
Number of HLA assignments (P group, two-field)
Ancestry HLA-A HLA-B HLA-C HLA-DRB1 HLA-DRB3/4/5 HLA-DQB1 HLA-DPB1
African/African
American (AFA)
362 966 370 020 347 465 373 023 72 964 361 723 333 978
Asian/Pacific Islands
(API)
1 263 239b 1 274 300 1 195 602 1 305 847 117 098 1 299 499 1 080 334
European/European
descent (EURO)

















1 229 127 1 248 774 1 149 774 1 286 614 128 841 1 195 557 966 013
Total 15 222 206 15 263 838 14 224 859 15 731 920 1 180 846 15 484 671 13 971 655
aAncestry designations were determined by each contributing registry.
bOdd number is because of removal of alleles having incorrect format/assignment not based on HLA nomenclature.
TABLE 2B Self-reported ancestrya of individuals included in the dataset and the number of totalb assignments represented by each
population group
Number of HLA assignments (total)
Ancestry HLA-A HLA-B HLA-C HLA-DRB1 HLA-DRB3/4/5 HLA-DQB1 HLA-DPB1
African/African
American (AFA)
388 476 388 579 389 619 389 241 198 134 378 275 336 535
Asian/Pacific Islands
(API)
1 291 125c 1 298 351 1 255 403 1 318 229 297 151 1 314 598 1 082 177
European/European
descent (EURO)
11 929 417 11 941 489 11 827 887 11 938 778 1 329 462 11 735 570 10 680 854
Middle East/North coast
of Africa (MENA)




700 632 700 912 690 043 700 830 400 002 678 680 581 973
Native American
populations (NAM)




1 320 493 1 320 714 1 302 662 1 321 251 226 038 1 227 926 969 187
Total 16 099 561 16 119 172 15 935 915 16 138 686 2 516 526 15 804 198 14 006 753
aAncestry designations were determined by each contributing registry.
bTotal assignments include HLA assignments at all levels of resolution as submitted by the registries.
cOdd number is because of removal of alleles having incorrect format/assignment not based on HLA nomenclature.
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number is based on the number of individuals assuming
two HLA assignments for each locus with the exception of
DRB3/DRB4/DRB5 (as described below). The total assign-
ments include HLA assignments at all levels of resolution
as submitted by the registries with some alleles removed
because of incorrect format or faulty nomenclature. The fre-
quency of each HLA assignment is calculated by dividing
the number of alleles for that assignment by the total num-
ber of assignments. In cases where assignments are merged
to form P or G groups, the individual assignments making
up the P or G group (eg, A*02:01:01:01 or A*02:09 assign-
ments when merged to form A*02:01P total) are not
included in the total number of assignments for the P or G
frequency evaluation (ie, allele assignments are not counted
more than once). Supporting Information Tables S8-S16
provide the allele counts by population group.
In the 2012 CWD publication (2.0.0 CWD),16 common
alleles were assigned based on presence in multiple, not
necessarily all, population groups with frequencies that
were known (Supporting Information Table S1). In general,
these alleles were observed at frequencies of >0.001 in refer-
ence population groups of at least 1500 individuals. Later
evaluations based on European17,19 or Chinese
populations18 were based on two-field designations. While
retaining the category designations, “common” alleles in
this study include those present at least 1 in 10 000 in any
population group or in the total dataset. This captures
almost all the alleles designated as common in the three
earlier studies as described in Results. We did not compare
3.0.0 CIWD to the CWD of the German stem cell donors
because of the overlap in samples from the DKMS donor
center and because the German data were obtained by
imputation, not by direct allele counting.19
A new category, consistent with that used by the Ger-
man registry as “well-documented 1” (WD1),19 termed
“intermediate” includes alleles found at frequencies less
than 1 in 10 000 but at least 1 in 100 000. It should be
noted that, because of the smaller groups typed for AFA,
MENA, and NAM, it was not possible to assign alleles to
the intermediate category as a single category without
having met the occurrence threshold for well-docu-
mented. So these groups only have two categories, com-
mon and well-documented.
We have reserved the definition of “well-docu-
mented” to include alleles that have been observed five
or more times in unrelated individuals but not at the
common or intermediate levels. The well-documented
category is independent of sample sizes of any population
group and includes alleles that are rare, but whose exis-
tence in multiple random individuals is not in question.
We refer to alleles in these three categories as CIWD.
HLA-DRB3/4/5 could not be evaluated for estimated fre-
quency as these loci were reported in total occurrence,
but could not sufficiently account for individuals who
were not tested or where the gene was not present or
homozygous. In addition, greater than 50% of the submit-
ted HLA-DRB3/4/5 typing contained allelic ambiguities.
Given these phenomena, only well-documented occur-
rences are provided.
Because alleles common to one or a few population
groups do not necessarily reach this minimum frequency
in the total population and because the dataset is heavily
weighted toward individuals of EURO ancestry, we have
chosen to base our summary CIWD assignments on the
most frequent category observed within the total or
within individual population groups. For example,
B*07:12 is well-documented in the overall population,
not-CIWD in most of the individual population groups
but common in AFA so the summary CIWD assignment
is common. The tables also provide frequency categories
based on the total population as well as categorizations
for each group.
3 | RESULTS
This update to the CWD allele catalog evaluates the fre-
quency of over 15.2 million two-field P group assign-
ments at each locus of HLA-A, -B, -DRB1, and -DQB1
in over 8 million individuals whose HLA types are
found in 20 worldwide hematopoietic stem cell regis-
tries listing their ancestries in seven categories
(Tables 1, 2a and 2b). Substantial data are also present
for HLA-C (14.2 million two-field) and -DPB1 (14.0
million) and for HLA-DRB3/4/5 (1.2 million two-field
assignments). Data used in this analysis are included in
Supporting Information tables and will also be posted
on a public web site (https://www.ihiw18.org/) so that
laboratories might perform their own analyses.
Table 3 describes the overall frequency of alleles at
each locus observed compared with the total number of
alleles in IPD-IMGT/HLA 3.31.0. About half of the
known two-field P group alleles are found within registry
databases (eg, 54% HLA-A alleles); about 25% are
assigned as CIWD (eg, 24% HLA-A alleles). HLA-DPB1
has the highest percentage of total alleles observed at 69%
with 41% overall assigned as CIWD. Figures 1 and 2
describe the number of alleles, at P (two-field) and G res-
olution, assigned to each frequency category.
4 | CIWD HLA ALLELES AT
TWO-FIELD (P) DESIGNATION
HLA-B and -DQB1 serve as examples of the two-field P
level resolution assignments for the current data
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compared with previous CWD reports (Table 4).16-18 The
analysis is based on over 15 million two-field assignments
at each locus (Table 2a).
Slightly more than half (n = 1853) of the two-field
P group HLA-B alleles of the total 3537 in IPD-IMGT/
HLA 3.31.0 are observed overall in the dataset, but
only 864 (24% of total) are assigned to a CIWD cate-
gory (Table 3, Figure 1). The number of HLA-B alleles
common at the two-field level are 195 (Table 4,
Supporting Information Table 3b). About 60% (119)
were considered common in 2.0.0 CWD; 74 were listed
as well-documented in 2.0.0. Two (B*08:12 (AFA),
B*37:04 (API)) were considered not-CWD in 2.0.0
CWD, likely because of the limited population groups
included at that time. Comparison to the EFI CWD
shows that 121 of the 195 were listed as common
(n = 61) or well-documented (n = 60) and 74 were not
included in the EFI CWD listing (Table 4). Compari-
son to the China CWD shows 114 of the 195 listed as
common (n = 54) or well-documented (n = 60) and
81 not listed. The alleles identified as common in the
three earlier CWD reports are largely included in the
current common listing (2.0.0 CWD 119/121; EFI
CWD 61/62; China CWD 54/54).
The intermediate HLA-B category includes 128 alleles
at the P level; 80 of these were categorized in 2.0.0 CWD
as common (n = 2) or well-documented (n = 78). Of the
48 intermediate alleles not included in 2.0.0 CWD, only
eight are listed by EFI CWD or China CWD (assigned as
well-documented).
HLA-B alleles categorized as well-documented at
two-field P level resolution total 541; 71 of them are
included in 2.0.0 CWD as well-documented. Of the
470 well-documented alleles not included in 2.0.0 CWD,

















HLA-A 2827 1521 53.8 673 23.8
HLA-B 3537 1853 52.4 864 24.4
HLA-C 2494 1366 54.8 602 24.1
HLA-DRB1 1559 817 52.4 422 27.1
HLA-DRB3 125 66 52.8 32 25.6
HLA-DRB4 63 17 27.0 10 15.9
HLA-DRB5 50 31 62.0 15 30.0
HLA-DQB1 669 384 57.4 179 26.8
HLA-DPB1 628 430 68.5 258 41.1





















FIGURE 1 Distribution of HLA
alleles into three frequency categories
(common, intermediate, well-
documented) at P group (two-field)
resolution
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120 are listed by EFI CWD and 13 additional alleles by
China CWD as well-documented. In total, 337 new alleles
are added to the well-documented listing.
Sixty-five alleles listed in one or more of the previous
three reports are not observed in five or more individuals in
the current study. All 65 alleles were assigned as well-
documented in the earlier studies: seven in 2.0.0 CWD,
15 in EFI CWD and 46 in China CWD. For example
B*40:25, listed as well-documented in all three prior studies,
was only observed once in registry databases (in EURO).
Almost 60% (57%; n = 384) of the two-field P group
HLA-DQB1 alleles of the total 669 in IPD-IMGT/HLA
3.31.0 are observed overall in the dataset, but only
179 (27% of total) are assigned to a CIWD category
(Table 3, Figure 1). HLA-DQB1 alleles common at the
two-field level number 29 based on the highest frequency
category found in any population group (Table 4,
Supporting Information Table 3f). About 66% (n = 19)
were considered common in 2.0.0 CWD; three were listed
as well-documented in 2.0.0 CWD. Seven were considered
not-CWD in 2.0.0 CWD. Comparison to the EFI CWD
shows that 22 of the 29 were listed as common (n = 17) or
well-documented (n = 5) and seven were not included in
the EFI CWD listing (Table 4). Comparison to the China
CWD shows 21 of the 29 listed as common (n = 15) or
well-documented (n = 6) and eight not listed. The alleles
identified as common in the three earlier CWD reports are
largely included in the current common listing (2.0.0
CWD 19/19; EFI CWD 17/20; China CWD 15/15).
The intermediate HLA-DQB1 category includes
31 alleles at the two-field P level; none was included in
the 2.0.0 CWD. Of the 31 intermediate alleles, only 10 are
listed by EFI CWD (two common, eight well-docu-
mented) and four by China CWD (well-documented).
HLA-DQB1 alleles categorized as well-documented at
two-field totaled 119: only one was included in 2.0.0
CWD as well-documented, 27 by EFI CWD (one com-
mon, 26 well-documented), and four by China CWD
(well-documented). In total, 91 new HLA-DQB1 alleles
were added to the well-documented listing.
Nine alleles designated as well-documented in early
studies were not included in the 3.0.0 CIWD. For exam-
ples, DQB1*03:27, listed as well-documented in China
CWD, was observed three times in this registry study
dataset (found in API), and DQB1*06:19, listed as well-
documented in EFI CWD, was observed four times
(API/EURO-2/UNK).
Similar findings are provided for HLA-A, -C, -DRB1,
and -DPB1 (Tables 3 and 4, Figure 1, Supporting Infor-
mation Table S3a, c, d, g). HLA-DRB3/4/5 two-field
groups are only categorized as well-documented because
of incomplete information at these loci.
5 | CIWD HLA ALLELES
AT G-LEVEL DESIGNATION
HLA-A and -DPB1 serve as examples of the G-level
assignments for the current data compared with previous
catalogs.16-18 The analysis is based on over 14 million
total assignments at each locus (Table 2b). Changes to
the categorization of the G-level assignments compared
with 2.0.0 CWD16 are modest.
In 2.0.0 CWD, 40 HLA-A G group alleles are common
and nine are well-documented (Supporting Information
Tables S4 and S5a). The current dataset lists 45 as com-
mon (Figure 2). This list also includes ten alleles that had
























FIGURE 2 Distribution of HLA
alleles into three frequency categories at G
group resolution












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































HURLEY ET AL. 525
CWD but that were considered common at that time. Five
well-documented alleles in 2.0.0 CWD (A*02:16:01G,
A*11:03, A*24:05:01G, A*24:14, A*66:03) are now classi-
fied as common with greatest frequency in AFA, API,
HIS, and/or NAM. Two G-level assignments are now con-
sidered intermediate; 2.0.0 CWD listed them as well-docu-
mented. Three G-level assignments are now well-
documented; previously two were well-documented and
one not-CWD (A*02:81:01G; observed now in EURO).
HLA-DPB1 has 32 common G groups; 26 were previ-
ously designated as common in 2.0.0 CWD; three had
been well-documented, and three were not-CWD. One of
the latter is a G group (DPB1*04:01:04G) described after
2012. Three alleles are now classified as intermediate and
all were previously assigned as well-documented in 2.0.0
CWD. One G group (DPB1*69:01:01G) remains well-
documented as categorized previously.
Similar findings for HLA-B, -C, -DRB1, and -DQB1
(Figure 2, Supporting Information Tables S4 and 5b, c, d,
f). HLA-DRB3/4/5 G groups are only categorized as well-
documented because of incomplete information at
these loci.
6 | CIWD HLA ALLELES AT
FULL-FIELD DESIGNATION
It was not possible to consistently determine the frequen-
cies of the alleles reported at full field designations. The
typing assignments submitted (Supporting Information
Tables S8-S16) illustrate the diversity of HLA assignments
that arise from typing volunteer donors over time
(2012-2018) and reflect the DNA sequence-based typing
strategy, including resolution requirements, used by each
registry. A good example of this is A*02:01:01:01 which is
very common when individuals are typed at a consistent
four-field resolution.23,24 In this multiple registry dataset,
A*02:01:01:01 was reported only 1294 times while
A*02:01:01G was reported over 3.7 million times. Over
40 (n = 43) alleles in the A*02:01:01G group are found in
this dataset but individually none are more common than
A*02:01:01:01 (eg, second most common A*02:01:01:05
appears 616 times in the total dataset). The total number of
assignments of alleles in the G group other than
A*02:01:01:01 is 1876. None of the individual alleles in the
A*02:01:01G group in Europeans appear in a frequency ≥1
in 10 000. In contrast, A*02:01:01G appears at frequency of
>1 in 4 (0.27) in Europeans. Therefore, most registries are
typing at a resolution of A*02:01:01G so there are insuffi-
cient data to accurately assess the frequency of
A*02:01:01:01 in this dataset. A similar situation is
observed for other alleles.
7 | NONEXPRESSED ALLELES
HLA-A and -DRB1 serve as an example of the non-
expressed allele assignments for the current data com-
pared with previous reports (Figure 3, Supporting
Information Tables S6 and S7a-g).16-18
Seventy-six nonexpressed two-field HLA-A alleles of
the total 186 in IPD-IMGT/HLA 3.31.0 are observed over-
all in the dataset, but only 32 (17% of total) are assigned to
a CIWD category. Most (n = 29) are well-documented.
One allele, A*23:19N, is common in AFA (Supporting
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FIGURE 3 Distribution of
nonexpressed HLA alleles into three
frequency categories and 1-4 occurrences
at P group resolution
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A*24:11N) are intermediate, found in the API group. The
remaining 44 nonexpressed HLA-A alleles are each
observed one to four times.
In 2.0.0 CWD, 6 well-documented and 1 common
(A*02:53N) nonexpressed HLA-A alleles are listed; six of
these are assigned 3.0.0 CIWD designations. Two of these
seven alleles are now classified as intermediate in API
(A*02:53N, A*24:11N). One (A*68:11N) has only two
entries in the present dataset. The EFI listing has no HLA-
A nonexpressed alleles listed; China CWD lists three as
well-documented: A*02:53N, A*11:69N, A*24:132N. Only
A*02:53N is observed in this study.
Of the 25 nonexpressed HLA-DRB1 alleles observed
overall out of the 52 in IPD-IMGT/HLA 3.31.0, only three
are observed more than five times: DRB1*07:10N,
DRB1*07:26N and DRB1*12:24N in the EURO group
(Supporting Information Tables S6 and 7d). There are no
HLA-DRB1 nonexpressed alleles listed in the three earlier
CWD reports.
Similar findings are observed for HLA-B, -C, -DQB1,
-DPB1 (Figure 3, Supporting Information Tables S6 and
7b,c, f, g). HLA-DRB3/4/5 nonexpressed alleles are only
categorized as well-documented because of incomplete
information at these loci. In 2.0.0 CWD, some of these
alleles, like DRB4*01:03N (ie, DRB4*01:03:01:02N) and
DRB5*01:08N, were designated as common.
8 | DISCUSSION
This update (3.0.0 CIWD) with over 8 million individuals
from 20 worldwide registries represents an enormous
increase in the information used to assess HLA frequencies.
It is based solely on HLA assignments collected by DNA
sequencing covering the time period 2012-2018. While the
number of individuals assessed in the 2012 version of CWD
alleles (2.0.0 CWD) was not described, the data from some of
the loci evaluated for the EFI and China CWD catalogs
derived from less than 1 million individuals (Supporting
Information Table S1). Further, two of the earlier reports
(2.0.0 and EFI CWD) relied partly on HLA assignments
derived from more resolution-limited DNA-based typing
methods (eg, probe hybridization or sequence-specific primer
typing) collected over earlier time periods. (Note: Advances
supporting cost-effective high volume DNA sequencing and
the efforts of registries to grow and diversify their volunteer
donor pool have made this CIWD effort possible).
8.1 | Population groups
Worldwide population diversity is increasing. In the United
States, for example, 13% of individuals were born in another
country and 25% of individuals list multiple ancestries
(https://www.census.gov, October 2018). In Sweden, 25% of
the population was either born abroad or had two parents
born abroad (https://www.scb.se/en/, 2018). Immigrants
represent large portions of the country's population in Saudi
Arabia (37%) and Singapore (46%). (http://www.un.org/en/
development/desa/population/migration/data/estimates2/
data/UN_MigrantStockTotal_2017.xlsx). For this reason,
access to worldwide HLA allele frequencies is essential to
serve diverse population groups. It should be noted, how-
ever, while the allele frequencies for individual population
groups are provided here, caution should be observed. Self-
identification of ancestry does not necessarily reflect genetic
ancestry.25 In cases where the ancestry of a patient or donor
may not be known, the laboratory might, for example, rely
on the highest frequency CIWD listings to determine if fur-
ther typing resolution is needed.
The sources of data used for this and the three ear-
lier catalogs differ dramatically although all included
some evaluation of unrelated hematopoietic stem cell
donors (Supporting Information Table S1). This
includes notable overlap of approximately 3.6 million
(68% of 5.3 million submitted) donors from DKMS Ger-
many present in the EFI catalog and this analysis. The
3.0.0 CIWD includes only individuals recruited as vol-
unteer donors in hematopoietic stem cell registries.
The 20 contributing registries are localized in five of
the six World Health Organization geographic regions
(Table 1). The African Region is not represented per se,
but individuals of recent African ancestry are found
within some of the submitted registry data. While the
population analyzed is more “global” in nature, clearly
future efforts need to be focused on geographic regions
under-represented in this analysis, specifically Africa
because of its high genetic diversity26 and Asia because
it is home to almost 60% of the world's population
https://population.un.org/wpp/Publications/Files/
WPP2019_Highlights.pdf (October 2019).
8.2 | Use of CIWD categories
The previous division of alleles into three categories,
common, well-documented and not-CWD, needed to be
reevaluated. In the past, there was a concern that some
alleles were either very rare or represented erroneous
sequences. For this reason, the well-documented cate-
gory captured less common alleles but those confirmed
as “real” by several (3-5) independent DNA sequences.
With the inclusion of large international registry data
of consecutive donor recruitment and with the focus
only on alleles identified by DNA sequencing, it is now
possible to estimate the frequency of HLA alleles.
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While retaining and expanding the category designa-
tions, we suggest that common alleles include those pre-
sent at ≥1 in 10 000. This broader definition of common
in 3.0.0 CIWD captures almost all the alleles designated
as common in the three earlier studies (classified as com-
mon in 3.0.0 CIWD: 92.0% 2.0.0 CWD, 96% EFI CWD,
100% China CWD; classified as intermediate in 3.0.0
CIWD: 4% 2.0.0 CWD, 2% EFI CWD).
Basing the second frequency category on five occur-
rences is unrealistic in terms of selecting a set of alleles
that should be routinely discriminated by typing
reagents. With this criterion, the well-documented cate-
gory would include, for example, 669 two-field P group
HLA-B alleles. Thus, we have introduced a new cate-
gory, intermediate, capturing alleles present at ≥1 in
100 000 (n = 128 for HLA-B). We suggest that the inter-
mediate category be included with the common category
when typing reagents are developed and/or further test-
ing is required to resolve alternative genotypes. Unfortu-
nately, three groups (AFA, MENA, NAM) did not have
sufficient numbers to use the intermediate category, so
more focused testing is needed to obtain a better esti-
mate of frequency in these groups. For these three
groups, to be conservative, well-documented alleles
might be included when further testing is required to
resolve ambiguity until better frequency estimates are
obtained.
Well-documented has been reserved for alleles that
are not in the common and intermediate categories but
that appear five or more times and are independent of
sample size. The well-documented (n = 541 for HLA-B P
group; n = 2 for HLA-B G group) and not-CIWD catego-
ries might be used to trigger repeat and/or extended test-
ing when assigned as an unambiguous genotype or when
all alternative genotypes include these two categories.
The 3.0.0 CIWD listing captures all of common alleles
listed by 2.0.0 CWD, EFI CWD and China CWD within
its three frequency categories. Overall, 3.0.0 CIWD
includes all but 3% of 2.0.0 CWD well-documented
alleles, 5% of the EFI CWD well-documented alleles, and
32% of the China CWD well-documented alleles. Thus,
3.0.0 CIWD bridges the 2.0.0 CWD and EFI catalogs
while the China CWD catalog continues to represent a
distinct collection of alleles. Future global catalogs should
increase their focus on the WHO Western Pacific region.
8.3 | Resolution
The focus on two-field P-level resolution HLA assign-
ments and G resolution assignments is guided by the
understanding that protein coding variation within the
ARD of the HLA molecules impacts antigenic peptide
binding and interactions with T cell receptors and killer
immunoglobulin-like receptors on natural killer cells.27-30
There is no strong evidence that variation outside of
these regions alone, with the exception of variation
resulting in nonexpressed alleles, plays a role in trans-
plant outcome and disease associations. Recent analyses
have focused on potential impact of mismatching patient
and donor at noncoding regions and regions outside the
ARD, although, because the number of evaluable cases
has been small, further investigation is needed.31-33 While
resolution of variation outside the ARD within hemato-
poietic stem cell registry volunteers allows a more refined
analysis of HLA diversity, this level of typing is not com-
monly used for matching donor and recipient.
When assessing the matching between donor and
recipient, an allele may be identified by the laboratory
that appears to encode an HLA protein mismatch but is
not listed in a CIWD table. Review of the primary CIWD
data provided in Supporting Information Tables S8-S16
will determine if the allele was observed in the 3.0.0
CIWD dataset. Note that some alleles once thought to be
common like A*02:17:01 and B*47:01:01:01 have been
deleted from the IPD-IMGT/HLA database and are no
longer listed (http://hla.alleles.org/nomenclature/index.
html). Also note that the alleles within a G group are
clustered together in the Supporting Information tables
so do not appear in numerical order in the tables. If listed
in Supporting Information Tables S8-S16, it is possible
that the allele lies within a P group and so is not listed in
Supporting Information Tables S3a-g. Two examples are
C*02:10 which is common and C*14:11 which is interme-
diate; neither is listed in Supporting Information Table 3c.
Both alleles exhibit nucleotide sequence variation in the
exons encoding the ARD but are “hidden” within the
C*02:02P and C*14:02P groups.
8.4 | Frequency of alleles within G
groups that encode different proteins
Without knowing the extent of the gene sequenced when
performing a typing, it is difficult to evaluate the fre-
quency of each allele within a G assignment that encodes
a different protein. For example, the A*02:49:01G group
includes A*02:49 and A*02:683. Because A*02:683 was
first assigned in 2017, A*02:49 was likely assigned based
on the sequence of the ARD-encoding exons only. Thus,
there is very little information on how often A*02:683 is
present. In a second example, A*02:22:01G includes
A*02:22:01:01, A*02:22:01:02, and A*02:104. A*02:22:01
was extended to a fourth field in 2017 but A*02:104 was
first described in 2006. In this case, because assignments
of A*02:22:01 could have resulted from a failure to
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consistently include the G when typing for the ARD-
encoding exons only, we cannot be confident that the
true frequency of A*02:104 can be evaluated.
However, when the assignment of the primary allele
in the G group is at four-field resolution, a frequency
comparison between alleles in the G cluster might be
made. This is the case for A*02:05:01G where assign-
ments include A*02:05:01:01 (Supporting Information
Table S8). In this case, when the non-ARD exons are
being evaluated, the frequency of G group alleles
A*02:179 and A*02:324 compared with that of
A*02:05:01:01 can be predicted. As in the case for most G
groups,23,24 the primary allele is observed most frequently
(A*02:05:01:01 appears 53 times in AFA) and secondary
alleles at lower frequency (A*02:179 appears 16 times in
this group and A*02:324 is not observed). A*02:16:01G
(A*02:16, A*02:131) is another example of where the
comparison can be made because there are more reports
of a secondary allele A*02:131 (n = 125) than the primary
allele giving the G group its name (A*02:16, n = 2)
in API.
8.5 | Nonexpressed alleles
The definition of high-resolution testing requires exclud-
ing all known nonexpressed alleles.34 Presently there are
464 class I and 124 HLA-DRB1, -DRB3, -DRB4, -DRB5,
-DQB1, -DPB1 nonexpressed alleles (IPD-IMGT/HLA
version 3.31.0) described. Excluding all nonexpressed
alleles that differ outside of the ARD-encoding domains
may require additional DNA testing or a serological assay
for expression. An alternative is to use allele frequencies
and/or known haplotypes to determine which of the non-
expressed alleles to consider in the testing protocol.
Unfortunately, frequency data of null alleles with key
variation outside the ARD can be limited and data on
haplotypes insufficient for diverse population groups.
The assignment of A*01:01:01G includes the non-
expressed alleles A*01:04:01:01N and A*01:04:01:02N
(often listed as A*01:04N in registry databases) together
with the very common A*01:01:01:01. The lack of expres-
sion results from an insertion in exon 4 in the two non-
expressed alleles which might not be readily tested by the
laboratory's routine assays. A*01:04N is observed a total
of 6 times in 5.6 million EURO individuals (ie, well-docu-
mented) and not observed in any other registry group, so
this frequency might justify a decision to assume these
nonexpressed alleles are not present without further test-
ing. However, it is unclear how often exon 4 was truly
evaluated by the registries' testing laboratories and
whether an accurate estimate of A*01:04N frequency is
known. When nonexpressed alleles appear in a specific
haplotype,19 this can be used to decide on further testing
although there are exceptions to usual haplotype
associations.
Alleles where variation potentially impacting protein
expression has been described but not yet documented
by further studies (ie, alleles with a Q designation) total
14 in the CIWD category. Three are intermediate in
API (A*32:11Q, C*15:32Q) and EURO (DQB1*02:53Q)
and the remainder well-documented. Because the varia-
tions in the three intermediate alleles impact the amino
acid sequences of the ARD, in addition to their ques-
tionable impact on protein expression, the lack of infor-
mation on expression should not hinder decisions
regarding their relevance in matching. Other, likely
rare, Q alleles may carry their key variation outside of
the ARD-encoding exons and it will be difficult to
assess matching without clarification of the impact on
protein expression.
8.6 | IMGT/HLA designation of CIWD to
extended allele names
In the IPD-IMGT/HLA database,11 the CWD status of
alleles has been updated as additional fields are added to
the allele name. For example, A*24:20 in the 2.0.0 CWD
is categorized as common. As that allele name became
extended to include additional fields, the IPD-IMGT/
HLA database assigned the allele with the 01 field
(s) (A*24:20:01:01) as common and A*24:20:01:02 as not
defined. In some cases, there is, at present, insufficient
typing assignments at the four-field level to determine
whether, for example, A*24:20:01:01 is common or not.
In the case of common A*30:02:01:01, two other alleles
with the same truncated designation in 2.0.0 CWD
(A*30:02:01) are also common (A*30:02:01:02,
A*30:02:01:03). In the case of A*80:01:01:01, that allele is
not common while A*80:01:01:02 is the more common
variant. Thus, the IPD-IMGT/HLA assignments for
alleles with longer names than those reported in the prior
versions of CIWD need further revision based on the data
provided here.
8.7 | Limitations of the catalog
Although this analysis represents the largest catalog of the
frequency of alleles to date, the data are heavily represen-
ted from registries in the United States and Germany. This
can influence the overall frequency of different alleles out-
side of what the actual frequency is in the broad geo-
graphic/ancestral/ethnic categories. In addition, many
parts of the world are not represented by data or include
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only a small relative number. However, this also provides
an opportunity for individual countries, donor registries or
individual studies of HLA diversity to compare the HLA
data with this global catalog to point out differences at a
more local level. Ancestry reporting is performed by many
registries at the time of donor recruitment via self-identifica-
tion, but is not implemented at some registries which results
in a large population group in the unknown category in this
analysis. Nomenclature that includes three and four fields
accompanies differential practices among registries, both in
typing methodology and standardization among testing of
donors joining a registry. For this study, we focused on two-
field P-level resolution summary of nomenclature but could
not provide an accurate assessment of frequency among
donors that were typed, for example, at four fields, as we
could not be confident in the denominator for such assess-
ment. HLA-DQA1 and -DPA1 loci did not have sufficient
submission of data, so although not summarized for this
study, could offer another phase for the 18th International
HLA and Immunogenetics Workshop study. Lastly, the
organization and submission of these data focused on
alleles, so is not able to provide the context of haplotype
data, but again offers additional opportunities for study.
9 | CONCLUSION
It has been suggested that mutation acts to create a pool
of rare alleles that might become important in the
defense against a new or evolving pathogen and, there-
fore, be selected to become more frequent.35 The charac-
teristics of variation at the HLA class I loci including
alleles that have likely arisen by single point mutations
has been described in detail based on the sequences of
the alleles submitted to the IPD-IMGT/HLA database.36
Estimates have been made about the total number of
HLA alleles (eg, 8-9 million class I alleles) that would be
found36 if we were able to sequence the HLA genes from
the 7.7 billion humans on earth (https://population.un.
org/wpp/, July 2019). The frequency of HLA alleles in
different populations reflects that population's evolution-
ary history9 and we see the impact of that history today
in the CIWD allele frequencies.
We offer the most comprehensive and collaborative
CWD catalog to date through the efforts of the 18th Inter-
national HLA and Immunogenetics Workshop and the
World Marrow Donor Association participating registries.
From a catalog that originated to help guide proficiency
testing of laboratories to a critical tool for testing develop-
ment and laboratory clinical decisions and registry policy,
we believe the data provided here will continue to be
instrumental in the understanding and use of HLA in its
many practices for health and research.
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